Drug
Amg 301
Amg 301: highest development phase Phase 2, developed by Amgen. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Amgen
Trials
| Drug | Phase | Indication |
|---|---|---|
| AMG 301 NCT03238781 | Phase 2 | Chronic Migraine or Episodic Migraine |
Latest
No recent events.
Follow Amg 301 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.